Karyopharm Therapeutics | KPTI - Ebit


Karyopharm Therapeutics reported $-26.28M in EBIT for its fiscal quarter ending in September of 2024.





Ebit Change Date
AbbVie USD 5.81B 4.36B Dec/2025
Abbott USD 2.54B 358M Dec/2025
Amgen USD 3.96B 464M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
J&J USD 5.11B 2.3B Dec/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Nektar Therapeutics USD -34.34M 3.68M Sep/2024
Novartis USD -9.19B 13.87B Jun/2025
Novartis USD 4.48B 343M Sep/2025
Pfizer USD 4.65B 71M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Takeda JPY 257.49B 568.56B Dec/2025
Tectonic Therapeutic USD -22.33M 4.03M Jun/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Xencor USD -47.52M 24.69M Sep/2025